HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CFSAN AER system

This article was originally published in The Rose Sheet

Executive Summary

Center for Food Safety & Applied Nutrition expects to have new adverse events reporting system for cosmetics, food and color additives and dietary supplements in place by May 2003, FDA reports. CFSAN Adverse Event Reporting System (CAER), which is undergoing pilot testing, will replace existing three AER systems. Older versions will remain in place until new system is implemented, agency says. Beginning on or after Sept. 16, CFSAN will send letters to companies notifying them when an AER involving one of their products has been received. Under Senate Agriculture Appropriations bill, CFSAN's AER system would receive $7.6 mil. in FY 2003 funding (1"The Rose Sheet" Aug. 5, 2002, In Brief)...

You may also be interested in...



FDA appropriations

Center for Food Safety and Applied Nutrition Adverse Events Reporting System would receive $7.6 mil. in FY 2003 funding under Senate Agriculture Appropriations bill, which unanimously passed out of committee July 25. CAERS funding represents $2 mil. more than budget request. Measure also provides $2 mil. for botanical research carried out by FDA, U-Miss. center. Bill calls for $149.3 mil. in funding for CFSAN and total FDA funding of $1.39 bil., which is $23.4 mil. more than budget request. Full Senate vote has yet to be scheduled...

Abbott Readying Vildagliptin ER In India Amid Price Competition

Abbott is developing an extended release version of vildagliptin in India, adding a new dimension to the market dynamics for the DPP-4 inhibitor, which has seen a key patent expire. Sustained release vildagliptin products from Wockhardt and Synokem also appear to be in the works.

AstraZeneca's Risky Lynparza Endpoint In Pancreatic Cancer Goes Before Advisory Cmte.

US FDA usually recommends using overall survival for pancreatic cancer drugs, but AstraZeneca choose progression-free survival; now ODAC will weigh in on whether the PARP inhibitor olaparib demonstrated a clinically meaningful impact. The firm cites enrollment and design challenges in the gBRCAm population as reasons for using PFS.

UsernamePublicRestriction

Register

RS010565

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel